How has our knowledge of the safety and efficacy of PCSCK9 inhibitors evolved, and how has the ODYSSEY Outcomes “treat-to-target” trial helped us translate these advances into the front lines of interventional cardiology practice?

How has our knowledge of the safety and efficacy of PCSCK9 inhibitors evolved, and how has the ODYSSEY Outcomes “treat-to-target” trial helped us translate these advances into the front lines of interventional cardiology practice?

CLICK HERE FOR CME CREDIT

How has our knowledge of the safety and efficacy of PCSCK9 inhibitors evolved, and how has the ODYSSEY Outcomes “treat-to-target” trial helped us translate these advances into the front lines of interventional cardiology practice?

Created by

CMEducation Resources IQ&A Cardiovascular Intelligence Zone | The Interventional Cardiologist's Perspective

Presenter

Phillipe Steg, MD

Phillipe Steg, MD

Professor of Cardiology Université Paris – Diderot, Sorbonne-Paris Cité Professor, National Heart and Lung Institute Imperial College, London, UK Director, Coronary Care Unit Hôpital Bichat Paris, France